Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | The importance risk stratification to enable risk-adapted therapy in MDS & CMML

Luis Aguirre • 5 Jun 2023
ASCO 2023
Chronic Myelomonocytic Leukemia Leukemia Myelodysplastic Syndromes Rare Diseases

Luis Aguirre, MD, Moffitt Cancer Center, Tampa, FL, explains the importance of applying risk stratification models to optimize treatment for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Luis Aguirre

1:34
Feasibility of the IPSS-M in CMML
Luis Aguirre • 5 Jun 2023
1:49
Emerging treatments under investigation for CMML
Luis Aguirre • 5 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals